A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies
- 27 March 2000
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 25 (7) , 697-703
- https://doi.org/10.1038/sj.bmt.1702239
Abstract
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.Keywords
This publication has 25 references indexed in Scilit:
- High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancerBone Marrow Transplantation, 1998
- High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.Journal of Clinical Oncology, 1997
- High-Dose Tri-Alkylator Chemotherapy With Autologous Stem Cell Rescue in Patients With Refractory MalignanciesJNCI Journal of the National Cancer Institute, 1990
- High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.Journal of Clinical Oncology, 1988
- High dose cisplatin and high dose carboplatin in refractory ovarian cancerCancer Treatment Reviews, 1985
- High–dose melphalan with autologous bone marrow transplant treatment of poor prognosis tumorsCancer, 1983
- SUMMARY OF RESULTS WITH TRIETHYLENE THIOPHOSPHORAMIDEAnnals of the New York Academy of Sciences, 1958
- Triethylenethiophosphoramide (Thio-TEPA) in the treatment of neoplastic diseaseCancer, 1957
- Chemotherapy of Solid Tumors with Triethylene ThiophosphoramideNew England Journal of Medicine, 1955
- Clinical studies on the carcinolytic action of triethylenephosphoramideCancer, 1953